EUVIMEDEUVIMED entdecken
Crossref

Risk Assessment of Cytomegalovirus Reactivation After Kidney Transplantation Under a Universal Preemptive Strategy in the Era of Intravenous Immunoglobulin‐Based Desensitization Therapy

Yu Kijima iD, Toshihito Hirai, Shuhei Nozaki, Takafumi Yagisawa iD, Ayaka Saito, Kohei Unagami, Kazuya Omoto, Tomokazu Shimizu, Toshio Takagi iD, Hideki Ishida

International Journal of Urology · 2026

DOI: 10.1111/iju.70342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Yu Kijima und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Kidney Transplantation, Immunoglobulins, Intravenous, Cytomegalovirus Infections, Virus Activation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) infection remains a key opportunistic complication after kidney transplantation. We evaluated risk factors for CMV reactivation in a universal preemptive strategy for the recent patient cohort including immunologically crossmatch positive high‐risk recipients who underwent Intravenous Immunoglobulin (IVIG)‐based desensitization with rituximab (Rit).

Methods

In this retrospective cohort study, 395 adult KTx recipients treated between 2019 and 2021 were enrolled. All 395 recipients were divided into 3 groups as follows: group 1 receiving IVIG (+)/Rit (+), n = 32 (8.1%); group 2 Rit (+) only, n = 270 (68.6%); group 3 receiving none, n = 93 (23.5%). The purpose of this study is to examine the influence of immunosuppressants including IVIG and/or Rit on CMV infection.

Results

Totally, CMV antigenemia was observed in 51 of 395 recipients (12.9%). Among them, 8 out of 32 recipients in group 1 (25.0%) showed CMV antigenemia, 29 out of 270 recipients in group 2 (10.7%), and 14 out of 93 recipients in group 3 (15.1%). There was a higher tendency of CMV antigenemia incidence in group 1, compared to groups 2 and 3, although not statistical significance. Univariate and multivariate logistic regression identified pre‐transplant CMV‐IgG seronegativity (OR 2.58; 95% CI 1.36–4.88; p = 0.004) and Immunological high‐risk (OR 2.56; 95% CI 1.10–5.95; p = 0.038) as independent risk factors for CMV reactivation.

Conclusions

Seronegative status and immunosuppression against high immunological risk increased reactivation risk. Prophylactic treatment could be useful to prevent postoperative early complication in highly sensitized recipients using IVIG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationImmunoglobulins, IntravenousCytomegalovirus InfectionsVirus ActivationCytomegalovirusDesensitization, ImmunologicPostoperative ComplicationsHumansRetrospective StudiesFemaleRisk AssessmentMiddle AgedRisk FactorsImmunosuppressive AgentsAdultMaleRituximabGraft Rejection

Stichwörter der Autor:innen

antigenemiacytomegalovirusintravenous immunoglobulinkidney transplantationpreemptive therapy

Substanzen

Immunoglobulins, IntravenousImmunosuppressive AgentsRituximab

Autor:innen und Institutionen

  • Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
  • Department of Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan.

ORCID-Profile: Yu Kijima, Takafumi Yagisawa, Toshio Takagi

Zitieren

APA

Kijima, Y., Hirai, T., Nozaki, S., Yagisawa, T., Saito, A., Unagami, K., Omoto, K., Shimizu, T., Takagi, T., & Ishida, H. (2026). Risk Assessment of Cytomegalovirus Reactivation After Kidney Transplantation Under a Universal Preemptive Strategy in the Era of Intravenous Immunoglobulin‐Based Desensitization Therapy. International Journal of Urology. https://doi.org/10.1111/iju.70342

Vancouver

Kijima Y, Hirai T, Nozaki S, Yagisawa T, Saito A, Unagami K, et al. Risk Assessment of Cytomegalovirus Reactivation After Kidney Transplantation Under a Universal Preemptive Strategy in the Era of Intravenous Immunoglobulin‐Based Desensitization Therapy. International Journal of Urology. 2026. doi:10.1111/iju.70342

BibTeX
@article{Kijima2026,
  author = {Kijima, Yu and Hirai, Toshihito and Nozaki, Shuhei and Yagisawa, Takafumi and Saito, Ayaka and Unagami, Kohei and Omoto, Kazuya and Shimizu, Tomokazu and Takagi, Toshio and Ishida, Hideki},
  title = {Risk Assessment of Cytomegalovirus Reactivation After Kidney Transplantation Under a Universal Preemptive Strategy in the Era of Intravenous Immunoglobulin‐Based Desensitization Therapy},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70342}
}
Kostenlos starten →